Vladimir Simov

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Top Venues

RSC medicinal chemistry

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Casey J Moure, Brandon A Vara, Mangeng M Cheng, Christopher Sondey, Eric S Muise, Eunsil Park, Julia Eulalia Vela Ramirez, Dan Su, Shanti D'Souza, Qingyun Yan, Charles S Yeung, Minjia Zhang, My Sam Mansueto, Douglas E Linn, Mark Buchanan, Robert Foti, Erin F DiMauro, Brian Long, Vladimir Simov, Evan R Barry
Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor. Molecular cancer therapeutics 23 (8) (2024)
Sydney L Rosenblum, Dalia M Soueid, George M Giambaşu, Steve Vander Roest, Alexander Pasternak, Erin F DiMauro, Vladimir Simov, Amanda L Garner
Live cell screening to identify RNA-binding small molecule inhibitors of the pre-let-7-Lin28 RNA-protein interaction. RSC medicinal chemistry 15 (5) (2024)
Sydney L Rosenblum, Dalia M Soueid, George M Giambaşu, Steve Vander Roest, Alexander Pasternak, Erin F DiMauro, Vladimir Simov, Amanda L Garner
Live cell screening to identify RNA-binding small molecule inhibitors of the pre-let-7-Lin28 RNA-protein interaction. RSC medicinal chemistry 15 (5) (2024)
Casey J Moure, Brandon A Vara, Mangeng M Cheng, Christopher Sondey, Eric S Muise, Eunsil Park, Julia Eulalia Vela Ramirez, Dan Su, Shanti D'Souza, Qingyun Yan, Charles S Yeung, Minjia Zhang, My Sam Mansueto, Douglas E Linn, Mark Buchanan, Robert Foti, Erin F DiMauro, Brian Long, Vladimir Simov, Evan R Barry
Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor. Molecular cancer therapeutics (2024)